Delivering on the Promise of Synthetic Biology

We lead the synthetic biology industry, having developed and successfully commercialized the most Lab-to-Market™ ingredients. Our sustainable ingredients are used in thousands of top global brands, including our own family of consumer brands in Clean Beauty and Health markets.

Press Releases
May 19, 2023

EMERYVILLE, Calif., May 19, 2023 Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™...

May 9, 2023

Core revenue of $56.1 million exceeded Q1 guidance of $49.9 million Cash operating expense down 4% compared to Q1 2022 and down 24% versus Q4 2022 Completed strategic partnership with Givaudan on...

More Releases

Events & Presentations
Corporate Governance

The Board of Directors of Amyris (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.

Full Corporate Governance

Sign up for our investor
relations email list:
Sign up to for our investor relations email list:
* Required Fields
Financial Reports
Stock Information
Investor FAQ
Analyst Coverage